Table 2.
Comparison between kidney transplant recipients treated with sotrovimab early from the onset of symptoms and those treated late
| ≤5 days | >5 days | ||
|---|---|---|---|
| Variable | (n = 46) | (n = 36) | P-value |
| Recipient age, median (IQR), years | 62.5 (52–69) | 66.5 (58–72) | .07 |
| Baseline kidney graft function | |||
| sCr, median (IQR), mg/dL | 1.7 (1.2–2.4) | 2.4 (1.5–3) | .04 |
| eGFR, median (IQR), mL/minute/1.73 m2 | 35 (21–53) | 24 (19–46) | .09 |
| Other comorbidities | |||
| BMI ≥30 kg/m2, n(%) | 11 (24.4) | 15 (44.1) | .06 |
| Cerebrovascular disease, n(%) | 1 (2.2) | 6 (16.7) | .02 |
| CCI, median (IQR) | 4 (3–6) | 6 (3–7) | .08 |
| Clinical features | |||
| Upper respiratory tract symptomsa, n(%) | 30 (65.2) | 31 (86.1) | .03 |
| Gastrointestinal symptoms, n(%) | 8 (14.4) | 20 (55.6) | <.001 |
| Dyspnea, n(%) | 15 (32.6) | 30 (83.3) | <.001 |
| Oxygen saturation at admission <95%, n(%) | 10 (21.7) | 25 (69.4) | .002 |
| Pneumonia, n(%) | 18 (39.1) | 35 (97.2) | <.001 |
| Lymphopenia, n(%) | 30 (66.7) | 32 (88.9) | .02 |
| Time from onset of symptoms to sotrovimab infusion, median (IQR), days | 2 (1–4) | 11.5 (8–17.7) | <.001 |
| Hospitalized, n(%) | 31 (67.4) | 36 (100) | <.001 |
| Additional COVID-19 therapy | |||
| Glucocorticoids, n(%) | 23 (50) | 31 (86.1) | .001 |
| Tocilizumab, n(%) | 3 (6.5) | 14 (38.9) | <.001 |
| COVID-19 outcomes | |||
| Ventilator support, n(%) | 1 (2.2) | 13 (36.1) | <.001 |
| ICU admission, n(%) | 1 (2.2) | 9 (25) | .002 |
| Dead, n(%) | 1 (2.2) | 6 (16.7) | .02 |
All the variables analyzed in Table 1 were compared. Only those with P < .1 are shown. BMI: body mass index; CCI: Charlson Comorbidity Index; COVID-19: coronavirus disease 2019; eGFR: estimated glomerular filtration rate; ICU: intensive care unit; IQR: interquartile range; sCr: serum creatinine.
aCough, sore throat, rhinorrhea, or expectoration.